Research ExplorerPublicationsComparing two lower-dose cisplatin programs for radio-chemot...

Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers

Standard

Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers. / Rades, Dirk; Seidl, Daniel; Janssen, Stefan; Strojan, Primoz; Karner, Katarina; Bajrovic, Amira; Hakim, Samer G; Wollenberg, Barbara; Schild, Steven E.

In: EUR ARCH OTO-RHINO-L, Vol. 274, No. 2, 02.2017, p. 1021-1027.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rades, D, Seidl, D, Janssen, S, Strojan, P, Karner, K, Bajrovic, A, Hakim, SG, Wollenberg, B & Schild, SE 2017, 'Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers', EUR ARCH OTO-RHINO-L, vol. 274, no. 2, pp. 1021-1027. https://doi.org/10.1007/s00405-016-4326-5

APA

Rades, D., Seidl, D., Janssen, S., Strojan, P., Karner, K., Bajrovic, A., Hakim, S. G., Wollenberg, B., & Schild, S. E. (2017). Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers. EUR ARCH OTO-RHINO-L, 274(2), 1021-1027. https://doi.org/10.1007/s00405-016-4326-5

Vancouver

Rades D, Seidl D, Janssen S, Strojan P, Karner K, Bajrovic A et al. Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers. EUR ARCH OTO-RHINO-L. 2017 Feb;274(2):1021-1027. https://doi.org/10.1007/s00405-016-4326-5

Bibtex

@article{eedf4607c26e4a9c85a34e39fb46531f,
title = "Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers",
abstract = "Radio-chemotherapy is a common treatment for locally advanced squamous cell head-and-neck cancers (LA-SCCHN). Cisplatin (100 mg/m(2)) every 3 weeks is very common but associated with considerable toxicity. Therefore, cisplatin programs with lower daily doses were introduced. There is a lack of studies comparing lower-dose programs. In this study, 85 patients receiving radio-chemotherapy with 20 mg/m(2) cisplatin on 5 days every 4 weeks (group A) were retrospectively compared to 85 patients receiving radio-chemotherapy with 30-40 mg/m(2) cisplatin weekly (group B). Groups were matched for nine factors including age, gender, performance score, tumor site, T-/N-category, surgery, hemoglobin before radio-chemotherapy, and radiation technique. One- and 3-year loco-regional control rates were 83 and 69 % in group A versus 74 and 63 % in group B (p = 0.12). One- and 3-year survival rates were 93 % and 73 % in group A versus 91 and 49 % in group B (p = 0.011). On multivariate analysis, survival was significantly better for group A (HR 1.17; p = 0.002). In groups A and B, 12 and 28 % of patients, respectively, did not receive a cumulative cisplatin dose ≥180 mg/m(2) (p = 0.016). Toxicity rates were not significantly different. On subgroup analyses, group A patients had better loco-regional control (p = 0.040) and survival (p = 0.005) than group B patients after definitive radio-chemotherapy. In patients receiving adjuvant radio-chemotherapy, outcomes were not significantly different. Thus, 20 mg/m(2) cisplatin on 5 days every 4 weeks resulted in better loco-regional control and survival in patients receiving definitive radio-chemotherapy and may be preferable for these patients. Confirmation of these results in a randomized trial is warranted.",
keywords = "Antineoplastic Agents, Cisplatin, Dose-Response Relationship, Drug, Female, Head and Neck Neoplasms, Humans, Male, Middle Aged, Neoplasm Staging, Radiotherapy, Adjuvant, Retrospective Studies, Treatment Outcome, Journal Article",
author = "Dirk Rades and Daniel Seidl and Stefan Janssen and Primoz Strojan and Katarina Karner and Amira Bajrovic and Hakim, {Samer G} and Barbara Wollenberg and Schild, {Steven E}",
year = "2017",
month = feb,
doi = "10.1007/s00405-016-4326-5",
language = "English",
volume = "274",
pages = "1021--1027",
journal = "EUR ARCH OTO-RHINO-L",
issn = "0937-4477",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers

AU - Rades, Dirk

AU - Seidl, Daniel

AU - Janssen, Stefan

AU - Strojan, Primoz

AU - Karner, Katarina

AU - Bajrovic, Amira

AU - Hakim, Samer G

AU - Wollenberg, Barbara

AU - Schild, Steven E

PY - 2017/2

Y1 - 2017/2

N2 - Radio-chemotherapy is a common treatment for locally advanced squamous cell head-and-neck cancers (LA-SCCHN). Cisplatin (100 mg/m(2)) every 3 weeks is very common but associated with considerable toxicity. Therefore, cisplatin programs with lower daily doses were introduced. There is a lack of studies comparing lower-dose programs. In this study, 85 patients receiving radio-chemotherapy with 20 mg/m(2) cisplatin on 5 days every 4 weeks (group A) were retrospectively compared to 85 patients receiving radio-chemotherapy with 30-40 mg/m(2) cisplatin weekly (group B). Groups were matched for nine factors including age, gender, performance score, tumor site, T-/N-category, surgery, hemoglobin before radio-chemotherapy, and radiation technique. One- and 3-year loco-regional control rates were 83 and 69 % in group A versus 74 and 63 % in group B (p = 0.12). One- and 3-year survival rates were 93 % and 73 % in group A versus 91 and 49 % in group B (p = 0.011). On multivariate analysis, survival was significantly better for group A (HR 1.17; p = 0.002). In groups A and B, 12 and 28 % of patients, respectively, did not receive a cumulative cisplatin dose ≥180 mg/m(2) (p = 0.016). Toxicity rates were not significantly different. On subgroup analyses, group A patients had better loco-regional control (p = 0.040) and survival (p = 0.005) than group B patients after definitive radio-chemotherapy. In patients receiving adjuvant radio-chemotherapy, outcomes were not significantly different. Thus, 20 mg/m(2) cisplatin on 5 days every 4 weeks resulted in better loco-regional control and survival in patients receiving definitive radio-chemotherapy and may be preferable for these patients. Confirmation of these results in a randomized trial is warranted.

AB - Radio-chemotherapy is a common treatment for locally advanced squamous cell head-and-neck cancers (LA-SCCHN). Cisplatin (100 mg/m(2)) every 3 weeks is very common but associated with considerable toxicity. Therefore, cisplatin programs with lower daily doses were introduced. There is a lack of studies comparing lower-dose programs. In this study, 85 patients receiving radio-chemotherapy with 20 mg/m(2) cisplatin on 5 days every 4 weeks (group A) were retrospectively compared to 85 patients receiving radio-chemotherapy with 30-40 mg/m(2) cisplatin weekly (group B). Groups were matched for nine factors including age, gender, performance score, tumor site, T-/N-category, surgery, hemoglobin before radio-chemotherapy, and radiation technique. One- and 3-year loco-regional control rates were 83 and 69 % in group A versus 74 and 63 % in group B (p = 0.12). One- and 3-year survival rates were 93 % and 73 % in group A versus 91 and 49 % in group B (p = 0.011). On multivariate analysis, survival was significantly better for group A (HR 1.17; p = 0.002). In groups A and B, 12 and 28 % of patients, respectively, did not receive a cumulative cisplatin dose ≥180 mg/m(2) (p = 0.016). Toxicity rates were not significantly different. On subgroup analyses, group A patients had better loco-regional control (p = 0.040) and survival (p = 0.005) than group B patients after definitive radio-chemotherapy. In patients receiving adjuvant radio-chemotherapy, outcomes were not significantly different. Thus, 20 mg/m(2) cisplatin on 5 days every 4 weeks resulted in better loco-regional control and survival in patients receiving definitive radio-chemotherapy and may be preferable for these patients. Confirmation of these results in a randomized trial is warranted.

KW - Antineoplastic Agents

KW - Cisplatin

KW - Dose-Response Relationship, Drug

KW - Female

KW - Head and Neck Neoplasms

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Radiotherapy, Adjuvant

KW - Retrospective Studies

KW - Treatment Outcome

KW - Journal Article

U2 - 10.1007/s00405-016-4326-5

DO - 10.1007/s00405-016-4326-5

M3 - SCORING: Journal article

C2 - 27687678

VL - 274

SP - 1021

EP - 1027

JO - EUR ARCH OTO-RHINO-L

JF - EUR ARCH OTO-RHINO-L

SN - 0937-4477

IS - 2

ER -